A Study of DLX105-DMP in Subjects With Plaque Psoriasis

• Status: Not yet recruiting
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: All

Summary

A Pilot, Open-Label Study in Subjects with Mild-to-Moderate Plaque Psoriasis to Investigate the Safety, Tolerability, and Preliminary Efficacy of a Four-Week Multidose Regimen of DLX105-DMP Administered to a Target Lesion

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: DelArrivo, Inc.
• Treatments: Unithiol

Criteria

Key Inclusion Criteria:

• Signed and dated informed consent.

• Subjects aged 18-75 years.

• Male subject, or if female, must be surgically sterile, post-menopausal, or using acceptable birth control.

• Stable chronic mild-to-moderate plaque psoriasis.

Key Exclusion Criteria:

• Non-plaque-type psoriasis only (e.g., pustular, erythrodermic and guttate psoriasis, palmar, or plantar) at Screening.

• Drug-induced psoriasis (i.e., new onset or exacerbation from beta-blockers, calcium channel inhibitors or lithium) within 3 months prior to Day 1.

• Ongoing use of psoriasis treatments or inadequate duration of washout prior to Day 1